Insider Selling: Illumina, Inc. (NASDAQ:ILMN) SVP Sells 155 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Phillip G. Febbo sold 155 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $300.00, for a total transaction of $46,500.00. Following the completion of the transaction, the senior vice president now owns 1,506 shares in the company, valued at approximately $451,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of ILMN traded up $0.69 during trading hours on Monday, reaching $306.67. 996,500 shares of the company traded hands, compared to its average volume of 1,030,535. The company’s fifty day moving average price is $301.21 and its two-hundred day moving average price is $310.03. The company has a market capitalization of $43.87 billion, a price-to-earnings ratio of 53.61, a price-to-earnings-growth ratio of 2.21 and a beta of 1.03. The company has a quick ratio of 6.15, a current ratio of 6.82 and a debt-to-equity ratio of 0.41. Illumina, Inc. has a 12 month low of $263.30 and a 12 month high of $380.76.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.53. The firm had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.52 EPS. On average, analysts expect that Illumina, Inc. will post 6.45 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in ILMN. Bath Savings Trust Co boosted its stake in shares of Illumina by 42.6% during the 2nd quarter. Bath Savings Trust Co now owns 1,062 shares of the life sciences company’s stock valued at $391,000 after purchasing an additional 317 shares in the last quarter. Winfield Associates Inc. boosted its stake in Illumina by 20.3% during the second quarter. Winfield Associates Inc. now owns 1,865 shares of the life sciences company’s stock worth $687,000 after acquiring an additional 315 shares in the last quarter. KAMES CAPITAL plc boosted its stake in Illumina by 58.8% during the second quarter. KAMES CAPITAL plc now owns 162,766 shares of the life sciences company’s stock worth $59,922,000 after acquiring an additional 60,287 shares in the last quarter. Copper Rock Capital Partners LLC bought a new stake in Illumina during the second quarter worth about $10,888,000. Finally, Zions Bancorporation N.A. boosted its stake in Illumina by 4.9% during the second quarter. Zions Bancorporation N.A. now owns 1,313 shares of the life sciences company’s stock worth $483,000 after acquiring an additional 61 shares in the last quarter. 91.09% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on ILMN shares. Cowen set a $320.00 price objective on shares of Illumina and gave the company a “buy” rating in a research report on Friday, October 25th. ValuEngine cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. Credit Suisse Group restated a “buy” rating and issued a $340.00 price objective on shares of Illumina in a research report on Wednesday, July 31st. Finally, Canaccord Genuity boosted their price objective on shares of Illumina from $300.00 to $310.00 and gave the company a “hold” rating in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. Illumina has an average rating of “Buy” and a consensus target price of $334.21.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: What is Depreciation?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.